推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 草甘膦原藥市場價(jià)格繼續(xù)保持平穩(wěn)。對于草甘膦原藥的銷售價(jià)格，目前不僅市場缺乏信心，生產(chǎn)企業(yè)也持不定態(tài)度。近期，草甘膦原藥的成交價(jià)格已經(jīng)距2010年市場公認(rèn)的最低價(jià)格18000元越來越近，雖然生產(chǎn)企業(yè)對該現(xiàn)象避而不談，但是市場分析者認(rèn)為，購銷雙方會盡快就價(jià)格一事進(jìn)行磋商。如果放任市場發(fā)展，在經(jīng)過漫長的7、8、9月之后，草甘膦原藥的市場價(jià)格會跌到何種地步，也未可知。
目前，生產(chǎn)企業(yè)維持原藥價(jià)格不變或者后期上漲的主要?jiǎng)恿θ匀辉诃h(huán)保。隨著環(huán)保壓力的增大，企業(yè)的違法成本越來越高，漲價(jià)意愿也越來越強(qiáng)烈，但是目前時(shí)機(jī)還不成熟：一是下游需求不足，二是馬上面臨高溫停車，使得草甘膦原藥的市場價(jià)格操作空間大大縮小，因而也就造成了目前這種市場價(jià)格不上不下的狀態(tài)。照目前市場的發(fā)展趨勢，后期草甘膦原藥的市場價(jià)格有可能會進(jìn)一步走低。
